A feared adverse effect of dyslipidaemia therapy by fibrates is myopathy. We examined the effect of fenofibrate (FF) on protein and amino acid metabolism. Rats received a low (50 mg/kg, LFFD) or high (300 mg/kg, HFFD) dose of FF or vehicle daily by oral gavage. Blood plasma, liver, and soleus and extensor digitorum longus muscles were analysed after 10 days. The FF-treated rats developed hepatomegaly associated with increased hepatic carnitine and ATP and AMP concentrations, decreased protein breakdown, and decreased concentrations of DNA and triglycerides. HFFD increased plasma ALT and AST activities. The weight and protein content of muscles in the HFFD group were lower compared with controls. In muscles of the LFFD group there were increased ATP and decreased AMP concentrations; in the HFFD group AMP was increased. In both FF-treated groups there were increased glycine, phenylalanine, and citrulline and decreased arginine and branched-chain keto acids (BCKA) in blood plasma. After HFFD there were decreased levels of branched-chain amino acids (BCAA; valine, leucine and isoleucine), methionine, and lysine and increased homocysteine. Decreased arginine and increased glycine concentrations were found in both muscles in FF-treated animals; in HFFD-treated animals lysine, methionine, and BCAA were decreased. We conclude that FF exerts protein-anabolic effects on the liver and catabolic effects on muscles. HFFD causes signs of hepatotoxicity, impairs energy and protein balance in muscles, and decreases BCAA, methionine, and lysine. It is suggested that increased glycine and decreased lysine and methionine levels are due to activated carnitine synthesis; decreased BCAA and BCKA levels are due to increased BCAA oxidation.

Department of Physiology Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator‐activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:658‐663. PubMed

Walker AE, Kaplon RE, Lucking SMS, et al. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension. 2012;60:1517‐1523. PubMed PMC

Fernández‐Miranda C, Pérez‐Carreras M, Colina F, et al. A pilot trial of fenofibrate for the treatment of non‐alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200‐205. PubMed

Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3C‐18C. PubMed

Hodel C. Myopathy and rhabdomyolysis with lipid‐lowering drugs. Toxicol Lett. 2002;128:159‐168. PubMed

Tahmaz M, Kumbasar B, Ergen K, et al. Acute renal failure secondary to fenofibrate monotherapy‐induced rhabdomyolysis. Ren Fail. 2007;29:927‐930. PubMed

Wang D, Wang Y. Fenofibrate monotherapy‐induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. Medicine (Baltimore). 2018;97:e0318. PubMed PMC

Scatena R, Bottoni P, Martorana GE, et al. Mitochondrial respiratory chain dysfunction, a non‐receptor‐mediated effect of synthetic PPAR‐ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun. 2004;319:967‐973. PubMed

Ohta T, Masutomi N, Tsutsui N, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate‐induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37:521‐535. PubMed

Paul HS, Adibi SA. Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation. J Clin Invest. 1979;64:405‐412. PubMed PMC

Kadota Y, Kazama S, Bajotto G, et al. Clofibrate‐induced reduction of plasma branched‐chain amino acid concentrations impairs glucose tolerance in rats. JPEN J Parenter Enteral Nutr. 2012;36:337‐343. PubMed

Paul HS, Adibi SA. Leucine oxidation and protein turnover in clofibrate‐induced muscle protein degradation in rats. J Clin Invest. 1980;65:1285‐1293. PubMed PMC

Sun B, Xie Y, Jiang J, et al. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. Lipids Health Dis. 2015;14:27. PubMed PMC

Holecek M, Siman P, Vodenicarovova M, et al. Alterations in protein and amino acid metabolism in rats fed a branched‐chain amino acid‐ or leucine‐enriched diet during postprandial and postabsorptive states. Nutr Metab (Lond). 2016;13:12. PubMed PMC

Holecek M, Sispera L. Glutamine deficiency in extracellular fluid exerts adverse effects on protein and amino acid metabolism in skeletal muscle of healthy, laparotomized, and septic rats. Amino Acids. 2014;46:1377‐1384. PubMed

Muthny T, Kovarik M, Sispera L, et al. Protein metabolism in slow‐ and fast‐twitch skeletal muscle during turpentine‐induced inflammation. Int J Exp Pathol. 2008;89:64‐71. PubMed PMC

Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956;62:315‐323. PubMed PMC

Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265‐275. PubMed

Alhomida AS, Duhaiman AS, Al‐Jafari AA, et al. Determination of L‐carnitine, acylcarnitine and total carnitine levels in plasma and tissues of camel (Camelus dromedarius). Comp Biochem Physiol B Biochem Mol Biol. 1995;111:441‐445. PubMed

Gomes‐Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin‐proteasome pathway by mild oxidative stress. Cancer Lett. 2002;180:69‐74. PubMed

Koohmaraie M, Kretchmar DH. Comparisons of four methods for quantification of lysosomal cysteine proteinase activities. J Anim Sci. 1990;68:2362‐2370. PubMed

Holecek M, Kovarik M. Alterations in protein metabolism and amino acid concentrations in rats fed by a high‐protein (casein‐enriched) diet ‐ effect of starvation. Food Chem Toxicol. 2011;49:3336‐3342. PubMed

Holeček M, Vodeničarovová M. Muscle wasting and branched‐chain amino acid, alpha‐ketoglutarate, and ATP depletion in a rat model of liver cirrhosis. Int J Exp Pathol. 2018;99:274‐281. PubMed PMC

Nseir W, Mograbi J, Ghali M. Lipid‐lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012;57:1773‐1781. PubMed

van Zutphen T, Ciapaite J, Bloks VW, et al. Malnutrition‐associated liver steatosis and ATP depletion is caused by peroxisomal and mitochondrial dysfunction. J Hepatol. 2016;65:1198‐1208. PubMed

Ringseis R, Wen G, Eder K. Regulation of genes involved in carnitine homeostasis by PPARα across different species (rat, mouse, pig, cattle, chicken, and human). PPAR Res. 2012;2012: 868317. PubMed PMC

Paul HS, Gleditsch CE, Adibi SA. Mechanism of increased hepatic concentration of carnitine by clofibrate. Am J Physiol. 1986;251:E311‐E315. PubMed

Berglund ED, Lee‐Young RS, Lustig DG, et al. Hepatic energy state is regulated by glucagon receptor signaling in mice. J Clin Invest. 2009;119:2412‐2422. PubMed PMC

Bissonnette R, Treacy E, Rozen R, et al. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 2001;155:455‐462. PubMed

Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid‐lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf. 2004;3:101‐111. PubMed

Ishiguro H, Katano Y, Nakano I, et al. Clofibrate treatment promotes branched‐chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E‐BP1, and S6K1 in rat liver. Life Sci. 2006;79:737‐743. PubMed

Paul HS, Liu WQ, Adibi SA. Alteration in gene expression of branched‐chain keto acid dehydrogenase kinase but not in gene expression of its substrate in the liver of clofibrate‐treated rats. Biochem J. 1996;317:411‐417. PubMed PMC

Kobayashi R, Murakami T, Obayashi M, et al. Clofibric acid stimulates branched‐chain amino acid catabolism by three mechanisms. Arch Biochem Biophys. 2002;407:231‐240. PubMed

Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132‐241. PubMed PMC

Watford M. Lowered concentrations of branched‐chain amino acids result in impaired growth and neurological problems: insights from a branched‐chain alpha‐keto acid dehydrogenase complex kinase‐deficient mouse model. Nutr Rev. 2007;65:167‐172. PubMed

Anthony TG, Reiter AK, Anthony JC, et al. Deficiency of dietary EAA preferentially inhibits mRNA translation of ribosomal proteins in liver of meal‐fed rats. Am J Physiol Endocrinol Metab. 2001;281:E430‐E439. PubMed

Iwasa M, Ishihara T, Mifuji‐Moroka R, et al. Elevation of branched‐chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment. Obes Res Clin Pract. 2015;9:293‐297. PubMed

van den Berg E, Flores‐Guerrero J, Gruppen E, et al. Non‐alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched‐chain amino acids. Nutrients. 2019;11(3):705. PubMed PMC

Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nature Med. 2011;17:448‐453. PubMed PMC

Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats

The role of skeletal muscle in the pathogenesis of altered concentrations of branched-chain amino acids (valine, leucine, and isoleucine) in liver cirrhosis, diabetes, and other diseases